Vagiannis, D.; Novotna, E.; Skarka, A.; Kammerer, S.; Küpper, J.-H.; Chen, S.; Guo, L.; Staud, F.; Hofman, J.
Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers 2020, 12, 813.
https://doi.org/10.3390/cancers12040813
AMA Style
Vagiannis D, Novotna E, Skarka A, Kammerer S, Küpper J-H, Chen S, Guo L, Staud F, Hofman J.
Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers. 2020; 12(4):813.
https://doi.org/10.3390/cancers12040813
Chicago/Turabian Style
Vagiannis, Dimitrios, Eva Novotna, Adam Skarka, Sarah Kammerer, Jan-Heiner Küpper, Si Chen, Lei Guo, Frantisek Staud, and Jakub Hofman.
2020. "Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme" Cancers 12, no. 4: 813.
https://doi.org/10.3390/cancers12040813
APA Style
Vagiannis, D., Novotna, E., Skarka, A., Kammerer, S., Küpper, J.-H., Chen, S., Guo, L., Staud, F., & Hofman, J.
(2020). Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers, 12(4), 813.
https://doi.org/10.3390/cancers12040813